30 Heart Attack Clinical Trials in Palo Alto, CA (2026)

Q: How do I join a clinical trial in Palo Alto?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you.

Recruiting Heart Attack Studies in Palo Alto

NCT05254743Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment...

Palo Alto, CAPHASE3737 participantsLoxo Oncology, Inc.

View Study Details

NCT06943872Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia...

Palo Alto, CAPHASE3630 participantsBeiGene

View Study Details

NCT04988555Recruiting

A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in adult patients with acute leukemia....

Palo Alto, CAPHASE1606 participantsSumitomo Pharma America, Inc.

View Study Details

NCT06615050Recruiting

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning ...

Palo Alto, CAPHASE3572 participantsIncyte Corporation

View Study Details

NCT04910685Recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants w...

Palo Alto, CAPHASE2534 participantsBlueprint Medicines Corporation

View Study Details

NCT05865301Recruiting

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozog...

Palo Alto, CA500 participantsStanford University

View Study Details

NCT07277231Recruiting

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration...

Palo Alto, CAPHASE3500 participantsBeOne Medicines

View Study Details

NCT06973187Recruiting

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or smal...

Palo Alto, CAPHASE3500 participantsBeOne Medicines

View Study Details

NCT04065399Recruiting

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled...

Palo Alto, CAPHASE1447 participantsSyndax Pharmaceuticals

View Study Details

NCT01790152Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory ...

Palo Alto, CA420 participantsChildren's Oncology Group

View Study Details

NCT06456346Recruiting

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreduct...

Palo Alto, CAPHASE3300 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06588478Recruiting

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (S...

Palo Alto, CAPHASE2249 participantsLoxo Oncology, Inc.

View Study Details

NCT06368817Recruiting

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy us...

Palo Alto, CAPHASE2240 participantsChildren's Oncology Group

View Study Details

NCT03850574Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelod...

Palo Alto, CAPHASE1240 participantsAptose Biosciences Inc.

View Study Details

NCT06137118Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in par...

Palo Alto, CAPHASE1236 participantsAstraZeneca

View Study Details

NCT07281079Recruiting

A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

This Phase 3, randomized, double-blind, parallel-group (2-arm), placebo-controlled, multicenter study will evaluate the efficacy and safety of NNZ-2591 compared to placebo in pediatric participants wi...

Palo Alto, CAPHASE3160 participantsNeuren Pharmaceuticals Limited

View Study Details

NCT06271512Recruiting

A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel

The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the l...

Palo Alto, CA150 participantsGenetix Biotherapeutics Inc.

View Study Details

NCT06098430Recruiting

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This study aims to measure longitudinal sy...

Palo Alto, CA100 participantsSt. Jude Children's Research Hospital

View Study Details

NCT05848687Recruiting

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets...

Palo Alto, CAPHASE190 participantsTanja Andrea Gruber

View Study Details

NCT07190365Recruiting

Goal-oriented Telehealth Rehabilitation of Executive Functioning for Veterans With Chronic TBI

Provision of interventions that address cognitive and emotional problems faced by Veterans with history of TBI pursuing community reintegration is an important concern for VA. Using telerehabilitation...

Palo Alto, CANA80 participantsVA Office of Research and Development

View Study Details

NCT05295433Recruiting

An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

The primary objective of this study is to evaluate the long-term safety of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT...

Palo Alto, CAPHASE156 participantsModernaTX, Inc.

View Study Details

NCT06005038Recruiting

CogT pSOPT Intervention Study

(JUSTIFICATION: This is the R33 stage of an NIH funded R21/R33 study. R21 stage (IRB-61727) was focused on intervention development; R33 stage will focus on pilot testing the effect of the interventio...

Palo Alto, CAPHASE150 participantsStanford University

View Study Details

NCT06283745Recruiting

Randomized Clinical Trial of Intranasal Injection of Platelet-Rich Plasma for Treatment of Parosmia

This randomized clinical trial will evaluate the benefit of platelet-rich plasma (PRP) in the treatment of qualitative olfactory dysfunction (parosmia). PRP can be isolated from a patient's own blood ...

Palo Alto, CANA40 participantsStanford University

View Study Details

NCT06327685Recruiting

Avapritinib With Decitabine in Patients With SM-AHN

Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to contr...

Palo Alto, CAPHASE134 participantsH. Lee Moffitt Cancer Center and Research Institute

View Study Details

NCT06551584Recruiting

Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis....

Palo Alto, CAPHASE124 participantsStanford University

View Study Details

NCT06561152Recruiting

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

To determine the efficacy of the combination of tagraxofusp, cladribine, and cytarabine....

Palo Alto, CAPHASE120 participantsStanford University

View Study Details

NCT05642455Recruiting

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers....

Palo Alto, CAPHASE120 participantsAdaptimmune

View Study Details

NCT06248515Recruiting

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therap...

Palo Alto, CAPHASE218 participantsGeorgetown University

View Study Details

NCT05068674Recruiting

Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction

This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left vent...

Palo Alto, CAPHASE118 participantsJoseph C. Wu

View Study Details

NCT05188170Recruiting

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia....

Palo Alto, CAPHASE116 participantsStanford University

View Study Details

About Heart Attack Clinical Trials in Palo Alto

A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.

There are currently 30 heart attack clinical trials recruiting participants in Palo Alto, CA. These studies are seeking a combined 7,587 participants. Research is being sponsored by Loxo Oncology, Inc., BeiGene, Sumitomo Pharma America, Inc. and 19 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Heart Attack Clinical Trials in Palo Alto — FAQ

Are there heart attack clinical trials in Palo Alto?

Yes, there are 30 heart attack clinical trials currently recruiting in Palo Alto, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Palo Alto?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you about next steps.

Are clinical trials in Palo Alto free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Palo Alto studies also compensate for your time and travel.

What heart attack treatments are being tested?

The 30 active trials in Palo Alto are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.

Data updated July 17, 2026 from ClinicalTrials.gov